Company intelligence / Profile preview

Immunocan

Shanghai, China

Ownership: Private
Development stage: Other

Overview

Immunocan's platforms (e.g., ImmuMab® Mouse, ImmuMab Heavy®, ImmuMab HKL, ImmuAlpaca® Mouse) have enabled robust in vivo generation of fully human and alpaca-derived antibodies. The first candidate molecules have demonstrated superior anti-tumor efficacy in in vivo assays, outperforming benchmark Phase III molecules. The platforms are widely licensed to partners for discovery purposes, though no Immunocan-originated therapeutics are yet in human clinical trials.

Modalities: Monoclonal antibodyBispecific monoclonal antibodyNanobody therapyAntibody-drug conjugateProtein
Industry: Drug Discovery Services

Partnerships

Multiple undisclosed pharma/biotech partners using ImmuMab® and other platforms for discovery

Beyond the preview

Go deeper on Immunocan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunocan.

Explore the full profile